Chapter
FDA and Conflict of Interest in Drug Approvals
1:38:40 - 1:47:11 (08:31)
The head of the FDA, Center for Drug Evaluation and Research issued a statement to loosen the prohibition of financial ties of interest with drug companies. Meanwhile, the target for drug development for Alzheimer's disease has been reducing amyloid plaques in the brain to prevent the progression of low-grade Alzheimer's disease.
Clips
The development of drugs for Alzheimer's disease focuses on reducing amyloid plaques in the brain, but this surrogate endpoint is known by the FDA not to be a valid clinical endpoint indicator.
1:38:40 - 1:43:49 (05:09)
Summary
The development of drugs for Alzheimer's disease focuses on reducing amyloid plaques in the brain, but this surrogate endpoint is known by the FDA not to be a valid clinical endpoint indicator. Additionally, there is a revolving door between Pfizer, FDA, and CDC, raising concerns about conflicts of interest.
ChapterFDA and Conflict of Interest in Drug Approvals
Episode#263 – John Abramson: Big Pharma
PodcastLex Fridman Podcast
The FDA is considering loosening the financial conflict of interest restrictions with drug companies, according to a statement by the head of the Bureau of the FDA, who suggested that this would lead to less emotional responses in these situations.
1:43:49 - 1:47:11 (03:22)
Summary
The FDA is considering loosening the financial conflict of interest restrictions with drug companies, according to a statement by the head of the Bureau of the FDA, who suggested that this would lead to less emotional responses in these situations. This raises concerns about the potential influence of these conflicts on advisory committee decisions.